increase healthy for The full of for base existing year today. pre-pandemic the year was levels. customers joining were systems. XXXX. for you fundamentals and of concurrently growth and us the solid, our growth approached utilization Installed full Procedure QX Thank in business
in robotics and products through investments instruments, indication expansions. our flexible multi-port, and ecosystems development single-port accessories, product extended Our new digital
mitigated the partners supply operations year. our persisted through and the chain work fine the that teams Finally, challenges largely supply of
and as the general the and bariatric XX% Turning procedures. such saw to included Areas first United year. We benign in full for quarter States, procedures particularly surgery, cholecystectomy of the repair. hernia strength procedure growth surgery
Colon rectal data this outside US beyond of access. to products to our the market our the We accretive was Strong continued. performance. urology also growth global and procedure organization, diversification strategic in our ecosystems and trials, clinical growth attribute value investments and
Procedure declining through Regionally, the Japan, United and wave growth China the the November India States, hampered the in was starting of out year. in quarter end XXXX. progressively stood procedures with Europe in COVID by and in QX,
strength, period, SP Ion gynecology Korea. in Global XXXX. with the XXXX in moved compound both recovery compared procedures over showed three-year continued core with of annual growth XXX% with the XX% grew urology same growth its coming and of year, toward exceeding growth the areas majority their in and from procedure procedures XXXX, rates
capital placed XXX QX the we XXX front, in compared QX On with XXXX. systems in
X,XXX For systems with the in year, we XXXX. placed full X,XXX compared
and for was for in SP Our growth XX% for base rate XXXX. Ion XXX% installed multiport, XX%
additional for our programs we sustained strong for demand variable in placement now and capacity Ion in with our capital as capacity multiple Ion to and their hospitals indications. in demand expanding Overall, operating trends continue systems SP showed pursue interest for multiport several additional
organization and predictor SP flat for XX% incorporated X% System in by the in roughly year, measured QX and increased utilization for utilization learnings. for utilization multiport as important grew was demand X% our Ion. year-over-year is over future Utilization an however, of year the
third-generation the trade-in multiport grew on XXXX. finances, dollar population decline the the Touching impacted in the the by was of our X% systems. strength Revenue and in revenue of year of
manufacturing platforms and and higher continued commercial investments growth of our R&D reflecting of that capital global our by of guidance products, the footprint. support at the and end expansion landed capabilities, spend amortization our driven expenses expansion Our of our digital
capital have several care we to procedures supply systems the to have become using continue in standard scale. our we the company as been globe the an build own expenditures This several as increasing of investment is our countries. important Structurally, at industrial
have key robust capital-intensive technologies, instrument than allow of dependability, robust accessory customers. us a chain, market important supply in increased our pipelines, to our support business our vertically and make and serve digital investments bring technologies industrial These attractive a products chain years costs. supply lower We products and that more software The been develop past, ownership to and of product integrating imaging to and points. include at price more strategic investments more
through take to the enable also procedures, example, of efforts mind. to starts our I'd in our in Intuitive investments. the quadruple like our general a pursuit specific walk for in Coordinating aim moment with customers' those platform surgery. end to
systems for time. We over new functionality design addition all of our to allow the
Vinci our products. For new accessories, clearances, a our the da multiport model and X, instruments philosophy new enabled new adding generation platform, fourth da Xi strengthen and by imaging capabilities, software us new Vinci design has to this regulatory new with continuously
of a enabler discussed products which million in XXXX revenue $XXX our of surgery as These year in in the revenue ago. XX% with lot as are a minute of approximately stapling instruments well contributed growth our include the and growth key instruments, advanced general energy
fourth-generation clinical indications representative launch. to States in since United our platform its We added multiport procedure the XX
States spans for surgical now indications categories platforms United indications the multiport multiport and total over Our today. procedure in six XX
and Intuitive app. integrating launch training and Intuitive roughly significant smaller the since upgrades. have Xi of Hub My We systems next-generation routinely operating releases platform products, our XX OS We been reality Endoscope launched digital virtual our with fourth-generation software and including dozens improve visualization, Plus,
capabilities. and launch invest software expect in platform operating Concurrently, system generations enhanced our year. additional significantly and bring we Gen multiport this compatible We to X products new new of that
system For programs, multi-port we follows. as our development prioritize
focusing highest on product improved while patient of sensing dependability robot targeting quality. surgical precision, outcomes, Our is imaging innovation core often in the and improvement and priority capability instrument and through
analytic for the products for digital power, acquisition personalized to operating improve Next, learning we services team's room, analysis efficiency and care designed teams usability, including care for surgical skill and and programs.
treat can finally, flexibility that we post add and the systems per launch. platforms design to the to And to cost lower total ecosystems future with designed capability episode. we their patient Next,
time moment, any In more investment and substantial global current required environment, and technology we're typically and to the are require core making progress. architecture good we're at These often Given the market. architectures one given multiyear that cycles, developing new the design clinical system than human review. validate trials beyond in regulatory changes
do in start we we launch not As currently year, a XXXX. multi-port system this new expect
unmet based cost support ability We're clinical US. and has the on growth lung manufacturability, Ion. Adoption its healthy in on of improving iron rapid its Turning biopsy. products to been robustness focused need meet the to an in to
for in Europe, dossier green in a We have submitted also channel. Korea China's a review and regulatory
pandemic clearance at expect in clearance given this XXXX. time time in Ion health in adjustments We for the on the in We don't Chinese care China Europe ongoing a have firm related forecast system.
opportunities development applications. clinical the Ion conducting a into and extend Ion to lung. for advanced future clinical platform is research also strong other We're with indications in
our completing the focus pulmonologists body an thoracic While for outside we opportunity provide on what the value in to surgeons. and robotics started is lung, our offers Ion flexible
PMDA with has SP, obtained supported platform, da in Japan. recently indications single-port broad and Vinci strong in clearance Our has Korea adoption
first months. expect in Japan of We in SP installs the coming
in dossier our notified da Europe midyear to submit Vinci our Next, we on XXXX. to body plan SP
clinical indications indications additional regulatory been currently SP utility We're with So of indications surgery. the on some in requirements pursuing surgery share trials, United far, for XXXX we'll in two, feedback customer in established. and our for has on and we're for SP colorectal strong these thoracic information pathway prospective trials the IDE beyond these them required for are use Korea. as conducting SP more the clinical healthy In multi-specialty States, have and
new R&D, categories We're to ones. leadership portfolio in invest we development have continuing where expansion under to significant and existing resources support in the positioned into
chain Our reduction will product cost support capital increase investments supply industrial scale. to global and robustness,
front, growth a the we'll rate hard relative enabling pursue turn Recognizing in are economic targeting foundational to conditions forecast, XXXX. XXXX On and leverage making we're XXXX deceleration SG&A to of for in to functions. are fixed cost we some investments,
improve We forma pro in the and margins operating fluctuate the next then over quarters expect several to mid-term.
product increased platforms; and supply, excellent follows; in of by from expanded quality training, provision new that services indications as and access scale. through adoption and XXXX from country productivity outstanding pandemic of the pursuit of we as emerge for launches our and second, procedures In market execution; increased are priorities functions pursuit defined closing, benefit continuity for third, and commercial first, performance and finally, focused our our stresses;
Jamie, through take turn will in time finances who now I'll greater over our the detail. to you
